PaulIraNadlerMD

PubMed

• 23 citations
  Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report
  Lisa Rogers, Patricia LoRusso, Paul I. Nadler, Ghaus M. Malik, Anthony F. Shields, William G. Kaelin> ;Journal of Neuro-Oncology. 2011 Jan 1
• 40 citations
  Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
  Tomislav Dragovich, Mark S. Huberman, Daniel D. Von Hoff, Eric K. Rowinsky, Paul I. Nadler, Debra L. Wood, Marta Hamilton, George Hage, Julie Wolf, Amita Patnaik> ;Cancer Chemotherapy and Pharmacology. 2007 Jul 1
• 22 citations
  Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
  Amita Patnaik, Debra L. Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry Schwartz, Muralidhar Beeram, Manuel Hidalgo, Monica M. M...> ;Clinical Cancer Research. 2006 Dec 15
• 27 citations
  A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy...
  Michael J. Borucki, John Spritzler, David M. Asmuth, John W. Gnann, Martin S. Hirsch, Mostafa Nokta, Francesca T. Aweeka, Paul I. Nadler, Fred R. Sattler, Beverly Alst...> ;Antiviral Research. 2004 Nov 1
• 6 citations
  Biologic response modulation by tumor necrosis factor alpha (TNFα) in a phase Ib trial in cancer patients
  T. Logan, William E. Gooding, Theresa L. Whiteside, Marc S. Ernstoff, Sandra S. Kaplan, Linda M. Miketic, Daniel R. Vlock, Cheryl Tompkins, Debra L. Wood, Paul I. Nadl...> ;Journal of Immunotherapy. 1997 Sep 1
• 27 citations
  A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion.
  Abraham Mittelman, C. Puccio, Gafney E, Nancy Coombe, Brinj Singh, Debra L. Wood, Paul I. Nadler, Tauseef Ahmed, Zalmen A. Arlin> ;Investigational New Drugs. 1992 Aug 1
• 134 citations
  Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant p...
  Gerald McMahon, Paul H. Ehrlich, Zeinab A. Moustafa, Linda A. McCarthy, Diane Dottavio, Mark D. Tolpin, Paul I. Nadler, Lars Östberg> ;Hepatology. 1992 May 1
• 10 citations
  In Vivo Administration of Tumor Necrosis Factor-α is Associated with Antiviral Activity in Human Peripheral Mononuclear Cells
  Mostafa Nokta, Debbie S. Matzke, Mark Jennings, Erich Schlick, Paul I. Nadler, Richard B. Pollard> ;Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine. 1991 Jun 1
• 28 citations
  Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients.
  William R. Drobyski, Mark Gottlieb, Donald R. Carrigan, Lars Ostberg, Mark Grebenau, Horst Schran, Paul Magid, Paul H. Ehrlich, Paul I. Nadler, Robert C. Ash> ;Transplantation. 1991 Jun 1
• 25 citations
  Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication.
  Mostafa Nokta, Mark D. Tolpin, Paul I. Nadler, Richard B. Pollard> ;Antiviral Research. 1991 Apr 1
• 8 citations
  Safety and Tolerability of Two Percent Cyclosporine (Sandimmune®) Ophthalmic Ointment in Normal Volunteers
  Suzanne Solch, Paul I. Nadler, Michael H. Silverman> ;Journal of Ocular Pharmacology. 1991 Jan 1
• Therapeutic Uses of Macrophage Colony-Stimulating Factor
  Paul I. Nadler> ;Cancer Investigation. 1990 Jan 1
• 26 citations
  Clinical Trials with Human Tumor Necrosis Factor: In Vivo and In Vitro Effects on Human Mononuclear Phagocyte Function
  Paul Conkling, Cynthia C. Chua, Paul Nadler, Charles S. Greenberg, Elissa Doty, Mary A. Misukonis, Arthur F. Haney, Robert C. Bast, J. Brice Weinberg> ;Cancer Research. 1988 Oct 1
• 7 citations
  Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in humans.
  Frank R. Witter, Amina S. Woods, M Diane Griffin, Craig R. Smith, Paul Nadler, Paul S. Lietman> ;Clinical Pharmacology and Therapeutics. 1988 Aug 1
• 21 citations
  Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
  Frank R. Witter, Florence M. Barouki, Diane E. Griffin, Paul Nadler, Amina S. Woods, Debra Wood, Paul S. Lietman> ;Clinical Pharmacology and Therapeutics. 1987 Nov 1
• 26 citations
  Time Course of Interferon Levels, Antiviral State, 2′,5′-Oligoadenylate Synthetase and Side Effects in Healthy Men
  Florence M. Barouki, Frank R. Witter, Diane E. Griffin, Paul I. Nadler, Amina S. Woods, Debra L. Wood, Paul S. Lietman> ;Journal of Interferon Research. 1987 Feb 1
• 7 citations
  Genetic control of immune response to staphylococcal nuclease. XII: Analysis of nuclease antigenic determinants using anti-nuclease monoclonal antibodies
  C Devaux, Paul I. Nadler, Geraldine G. Miller, David H. Sachs> ;Molecular and Cellular Biochemistry. 1985 Sep 1
• 88 citations
  Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.
  Robert J. Wills, Susana Dennis, Herbert E. Spiegel, Donald M Gibson, Paul I Nadler> ;Clinical Pharmacology and Therapeutics. 1984 May 1
• 9 citations
  The expression and functional involvement of nuclease-specific idiotype on nuclease-primed helper T cells
  Paul I. Nadler, Geraldine G. Miller, David H. Sachs, Richard J. Hodes> ;European Journal of Immunology. 1982 Jan 1
• 10 citations
  Modification of T cell antinuclease idiotype expression by in vivo administration of anti-idiotype.
  Geraldine G. P. Miller, Paul I. Nadler, Richard J. Hodes, David H. Sachs> ;The Journal of Experimental Medicine. 1982 Jan 1
• 29 citations
  T cell recognition in the mixed lymphocyte response. II. Ia-positive splenic adherent cells are required for non-I region-induced stimulation.
  Gerald B. Ahmann, Paul I. Nadler, A Birnkrant, Richard J. Hodes> ;Journal of Immunology. 1981 Dec 1
• 27 citations
  Induction of idiotype-bearing, nuclease-specific helper T cells by in vivo treatment with anti-idiotype.
  G G Miller, Paul I. Nadler, Yoshihiro Asano, Richard J. Hodes, David H. Sachs> ;The Journal of Experimental Medicine. 1981 Jul 1
• 6 citations
  Genetic control of antibody responses to TNP-nuclease in vitro.
  Paul I. Nadler, G P Miller, David H. Sachs, Richard J. Hodes> ;Journal of Immunology. 1981 May 1
• 43 citations
  T Cell Recognition in the Mixed Lymphocyte Response I. Non-T, Radiation-Resistant Splenic Adherent Cells Are the Predominant Stimulators in the Murine Mixed Lymphocyte...
  Gerald B. Ahmann, Paul I. Nadler, Alan Birnkrant, Richard J. Hodes> ;Journal of Immunology. 1979 Aug 1
• Ontogeny of murine accessory cells: Ia antigen expression and accessory cell function in in vitro primary antibody responses.
  Nadler, P. I., Klingenstein, R. J., Hodes, R. J.> ;J Immunol. 1980 Aug
• Join now to see all